10rx review

10rx publishes quarterly prices and identifies its operator and possible pharmacies. The per-month headlines are equivalents of larger upfront payments. Confirm the selected term before enrolling: it must be completed, and the cancellation cutoffs sit alongside more restrictive final-sale language.

10rx is a cash-pay telehealth platform whose October 1, 2026 terms name 10Rx, Inc. Its catalog includes sermorelin and NAD⁺ alongside other prescription products. Ask which independent clinician and pharmacy will handle the selected treatment.

The service is for adults 18 and older, subject to clinician approval. Its FAQ claims shipping to all 50 states; confirm eligibility for the particular treatment, required labs and payment timing. The provider page lists Wasef Health Physicians and named clinicians, without establishing who will review your case.

The FAQ names Optimal Balance, Hallandale and VialsRX. The October 1 terms list those plus GoGoMeds, Boothwyn, SmartScripts and The Pharmacy Hub. These are seller disclosures, not a confirmed assignment or independent credential check.

Sermorelin is advertised at $172.96/month equivalent, with $518.87 billed today for a quarterly plan. NAD⁺ injection is $116.31/month equivalent, with $348.93 billed today for a quarterly plan. The advertised packages include prescribed medication, provider evaluation, shipping and supplies; confirm labs and your prescribed supply. These are upfront quarterly payments.

The terms also cover one-, three-, six- and twelve-month commitments and require completion of the selected term. Initial cancellation is described as before prescribing; refills require 48 hours before pharmacy transmission. A separate clause makes prescription sales final from order placement. There are no partial-period refunds, and remedies for damaged, recalled or incorrectly dispensed orders are discretionary. Obtain the applicable cancellation and refund terms before paying.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Sermorelin, NAD⁺, glutathione and the GLP-1 products are compounding-pharmacy preparations, not therapeutically equivalent to any FDA-approved branded drug, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. Naming the pharmacies filling its orders is useful, because it gives you something to check. On the evidence, keep the products apart. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism, but the long-term human outcome data behind it stays thin. Injectable and intranasal NAD⁺ have no controlled human outcome trials at all; the forms with trial data are the oral precursors NR and NMN, and what those trials show is that they raise blood NAD⁺, not that raising it changes how you feel or age. Injectable glutathione has essentially no controlled human outcome evidence. Individual results vary.